Evidence map›Paper›PMID 34663429›Full record

ArticleDiabetology & metabolic syndrome2021

The best drug supplement for obesity treatment: a systematic review and network meta-analysis.

Nader Salari, Samira Jafari, Niloofar Darvishi, Elahe Valipour, Masoud Mohammadi, Kamran Mansouri, Shamarina Shohaimi

RetractedErratum issuedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Diabetology & metabolic syndrome, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Obesity and the risk of cardiometabolic diseases.Nature reviews. Cardiology · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Nader SalariDepartment of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Samira JafariStudent Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Niloofar DarvishiStudent Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Elahe ValipourZimagene Medical Genetics Laboratory, Avicenna St, Hamedan, Iran.
Masoud MohammadiDepartment of Nursing, School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. Masoud.mohammadi1989@yahoo.com.ORCID http://orcid.org/0000-0002-5722-8300
Kamran MansouriMedical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Shamarina ShohaimiDepartment of Biology, Faculty of Science, University Putra Malaysia, Serdang, Selangor, Malaysia.
Kermanshah University of Medical Sciences · IRUniversiti Putra Malaysia · MY

Funding

Deputy for Research and Technology, Kermanshah University of Medical Sciences 4000303
6 · The paper itself

Abstract

backgroundObesity is a complex disease with an increasing prevalence worldwide. There are different weight-management options for obesity treatment, including dietary control, exercise, surgery, and medication. Medications are always associated with different responses from different people. More safety and efficacy of drugs with fewer side effects are valuable for any clinical condition. In this systematic review and network meta-analysis, different anti-obesity drugs are compared to identify the most effective drug.

methodsAll relevant studies were extracted by searching national and international databases of SID, MagIran, ProQuest, PubMed, Science Direct, Scopus, Web of Science (WoS), and Google Scholar without time limit until October 2020. Finally, the meta-analysis was performed with the 11 remaining studies containing 14 different drug supplements. The standardized mean difference (SMD) was calculated at a 95% confidence interval (CI) to evaluate the effects of each treatment group compared with placebo. A random-effect model was used to evaluate the effect of individual studies on the final result. Heterogeneity and incompatibility of the network were assessed by Cochran's Q and Higgins I

resultsOur results showed that there were significant mean effects in people intervened with Phentermine 15.0 mg + Topiramate 92.0 mg, Phentermine 7.5 mg + Topiramate 46.0 mg, Pramlintide, Naltrexone + Bupropion 32, and Liraglutide, with SMD effects size = - 9.1, - 7.4, - 6.5, - 5.9, - 5.35, respectively.

conclusionThis study was performed to compare the effect of different drugs used for weight loss in obese patients. The most effective drugs for weight loss were phentermine and topiramate, pramlintide, naltrexone, bupropion, and liraglutide compared to placebo treatment, respectively. This study provides new insights into anti-obesity drugs and hopes to shed new light on future research to manage and treat obesity.

Indexed as

Network-meta analysisObesityTreatment

Identifiers

PMID34663429
PMCPMC8522222
OpenAlexW3205351698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.